Akebia Therapeutics (AKBA) Financials

$2.26 +0.11 (+4.86%)

As of 03:52 PM Eastern

Annual Income Statements for Akebia Therapeutics

This table shows Akebia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-94	-52	-69
Consolidated Net Income / (Loss)	-94	-52	-69
Net Income / (Loss) Continuing Operations	-94	-52	-69
Total Pre-Tax Income	-94	-52	-69
Total Operating Income	-81	-46	-50
Total Gross Profit	207	120	97
Total Revenue	292	195	160
Operating Revenue	292	195	160
Total Cost of Revenue	86	74	63
Operating Cost of Revenue	86	74	63
Total Operating Expenses	288	167	147
Selling, General & Admin Expense	139	100	107
Research & Development Expense	130	63	38
Other Operating Expenses / (Income)	3.18	3.24	3.22
Restructuring Charge	16	0.18	0.06
Total Other Income / (Expense), net	-13	-5.67	-19
Interest Expense	0.91	0.00	0.52
Interest & Investment Income	-16	-6.03	-18
Other Income / (Expense), net	3.15	0.36	-0.24
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.00	-	0.00
Basic Earnings per Share	($0.52)	($0.28)	($0.33)
Weighted Average Basic Shares Outstanding	182.78M	187.47M	210.95M
Diluted Earnings per Share	($0.52)	($0.28)	($0.33)
Weighted Average Diluted Shares Outstanding	182.78M	187.47M	210.95M
Weighted Average Basic & Diluted Shares Outstanding	184.25M	209.37M	236.23M

This table shows Akebia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-54	-6.07	-27	-11	-14	0.61	-18	-8.58	-20	-23
Consolidated Net Income / (Loss)	-54	-1.91	-27	-11	-14	0.61	-18	-8.58	-20	-23
Net Income / (Loss) Continuing Operations	-54	-1.91	-27	-11	-14	0.61	-18	-8.58	-20	-23
Total Pre-Tax Income	-55	-0.33	-27	-11	-14	0.61	-18	-8.58	-20	-23
Total Operating Income	-50	-4.87	-26	-9.00	-13	1.37	-15	-8.73	-13	-14
Total Gross Profit	10	112	20	39	24	38	21	27	23	26
Total Revenue	49	117	40	56	42	56	33	44	37	46
Operating Revenue	49	117	40	56	42	56	33	44	37	46
Total Cost of Revenue	38	5.58	20	17	18	19	12	17	14	20
Operating Cost of Revenue	38	5.58	20	17	18	19	12	17	14	20
Total Operating Expenses	61	109	45	48	37	36	36	35	36	40
Selling, General & Admin Expense	32	30	25	27	23	25	25	27	27	28
Research & Development Expense	28	76	20	20	13	9.87	9.73	7.65	8.49	12
Other Operating Expenses / (Income)	0.74	1.54	0.57	0.95	0.86	0.86	0.71	0.76	0.77	0.98
Total Other Income / (Expense), net	-4.86	-3.55	-1.28	-2.18	-1.45	-0.76	-3.05	0.14	-7.53	-8.50
Interest & Investment Income	-3.95	-6.70	-1.56	-1.64	-1.41	-1.42	-2.50	-2.15	-6.66	-6.88
Other Income / (Expense), net	-	-	0.28	-0.53	-0.04	0.66	-0.03	2.29	-0.87	-1.62
Basic Earnings per Share	($0.29)	($0.04)	($0.15)	($0.06)	($0.08)	$0.01	($0.09)	($0.04)	($0.10)	($0.10)
Weighted Average Basic Shares Outstanding	183.88M	182.78M	184.77M	186.82M	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M
Diluted Earnings per Share	($0.29)	($0.03)	($0.15)	($0.06)	($0.08)	$0.01	($0.09)	($0.04)	($0.10)	($0.10)
Weighted Average Diluted Shares Outstanding	183.88M	182.78M	184.77M	186.82M	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M
Weighted Average Basic & Diluted Shares Outstanding	183.96M	184.25M	0.00	188.31M	188.39M	209.37M	209.60M	210.29M	218.18M	236.23M

This table details how cash moves in and out of Akebia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-59	-49	8.97
Net Cash From Operating Activities	-73	-23	-41
Net Cash From Continuing Operating Activities	-73	-23	-41
Net Income / (Loss) Continuing Operations	-94	-52	-69
Consolidated Net Income / (Loss)	-94	-52	-69
Depreciation Expense	1.65	1.59	1.46
Amortization Expense	36	40	40
Non-Cash Adjustments To Reconcile Net Income	52	8.18	25
Changes in Operating Assets and Liabilities, net	-68	-21	-38
Net Cash From Investing Activities	-0.11	0.00	-0.03
Net Cash From Continuing Investing Activities	-0.11	0.00	-0.03
Purchase of Property, Plant & Equipment	-0.11	0.00	-0.03
Net Cash From Financing Activities	15	-25	50
Net Cash From Continuing Financing Activities	15	-25	50
Repayment of Debt	-33	-32	-38
Issuance of Debt	-	0.00	45
Issuance of Common Equity	7.53	6.79	43
Other Financing Activities, net	40	0.00	0.39
Cash Interest Paid	6.76	6.06	5.04

This table details how cash moves in and out of Akebia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	0.87	-55	-34	-4.37	-7.12	-3.60	-0.96	-2.46	-5.47	18
Net Cash From Operating Activities	34	-55	-18	3.63	-7.17	-2.31	-19	-10	-6.70	-4.47
Net Cash From Continuing Operating Activities	34	-55	-18	3.63	-7.17	-2.31	-19	-10	-6.70	-4.47
Net Income / (Loss) Continuing Operations	-54	-6.07	-27	-11	-14	0.61	-18	-8.58	-20	-23
Consolidated Net Income / (Loss)	-54	-6.07	-27	-11	-14	0.61	-18	-8.58	-20	-23
Depreciation Expense	0.41	0.41	0.40	0.40	0.40	0.39	0.36	0.40	0.36	0.34
Amortization Expense	9.01	8.72	9.01	9.01	9.01	13	9.01	9.01	9.01	13
Non-Cash Adjustments To Reconcile Net Income	22	12	3.76	2.92	1.09	0.42	3.59	3.48	12	5.96
Changes in Operating Assets and Liabilities, net	57	-70	-3.83	2.48	-3.17	-17	-14	-14	-7.66	-1.16
Net Cash From Investing Activities	-	-	0.00	-	-	-	0.00	-0.03	-0.00	-0.00
Net Cash From Continuing Investing Activities	-	-	0.00	-	-	-	0.00	-0.03	-0.00	-0.00
Purchase of Property, Plant & Equipment	-	-	-	-	-	-	-	-	-0.00	-0.00
Net Cash From Financing Activities	-33	-0.00	-16	-8.00	0.05	-1.29	18	7.64	1.22	22
Net Cash From Continuing Financing Activities	-33	-0.00	-16	-8.00	0.05	-1.29	18	7.64	1.22	22
Repayment of Debt	-33	-	-16	-8.00	-	-8.00	-37	-0.37	-0.52	0.00
Issuance of Common Equity	0.06	-0.00	0.03	-	0.05	6.71	19	-	1.75	22
Other Financing Activities, net	-	-	0.00	-	-	0.00	0.14	0.01	-	0.23

This table presents Akebia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	356	242	221
Total Current Assets	185	118	114
Cash & Equivalents	90	43	52
Accounts Receivable	40	39	34
Inventories, net	22	16	16
Prepaid Expenses	33	20	11
Plant, Property, & Equipment, net	5.21	3.63	2.20
Total Noncurrent Assets	166	120	105
Goodwill	59	59	59
Intangible Assets	72	36	0.00
Other Noncurrent Operating Assets	35	25	46
Total Liabilities & Shareholders' Equity	356	242	221
Total Liabilities	351	272	270
Total Current Liabilities	130	100	81
Short-Term Debt	32	18	0.00
Accounts Payable	18	15	15
Accrued Expenses	76	68	63
Other Current Liabilities	-	0.00	2.27
Total Noncurrent Liabilities	221	172	189
Long-Term Debt	34	17	39
Noncurrent Deferred Revenue	43	43	0.00
Other Noncurrent Operating Liabilities	144	112	150
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	5.23	-31	-49
Total Preferred & Common Equity	5.23	-31	-49
Preferred Stock	0.00	0.00	0.00
Total Common Equity	5.23	-31	-49
Common Stock	1,562	1,578	1,629
Retained Earnings	-1,557	-1,609	-1,678
Accumulated Other Comprehensive Income / (Loss)	0.01	0.01	0.01

This table presents Akebia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	436	281	254	235	225	220	207
Total Current Assets	238	121	118	110	113	112	100
Cash & Equivalents	145	0.00	54	47	42	39	34
Accounts Receivable	23	19	20	23	27	30	32
Inventories, net	40	20	21	18	26	24	20
Prepaid Expenses	30	25	24	22	19	19	13
Plant, Property, & Equipment, net	5.62	0.00	4.42	4.02	3.27	2.90	2.53
Total Noncurrent Assets	193	59	131	121	109	105	104
Goodwill	55	59	59	59	59	59	59
Intangible Assets	81	0.00	54	45	27	18	9.01
Other Noncurrent Operating Assets	57	0.00	18	17	23	28	36
Total Liabilities & Shareholders' Equity	436	281	254	235	225	220	207
Total Liabilities	422	300	281	274	253	254	258
Total Current Liabilities	188	88	92	80	66	107	66
Short-Term Debt	66	0.00	24	8.00	0.00	0.00	0.00
Accounts Payable	20	0.00	12	9.04	12	10	13
Accrued Expenses	87	51	56	63	54	54	52
Total Noncurrent Liabilities	234	17	188	195	186	147	192
Long-Term Debt	-	0.00	18	35	30	38	38
Noncurrent Deferred Revenue	43	0.00	43	43	43	0.00	0.00
Other Noncurrent Operating Liabilities	191	17	127	117	113	109	153
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	14	-1,584	-27	-39	-27	-34	-50
Total Preferred & Common Equity	14	-19	-27	-39	-27	-34	-50
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	14	-1,584	-27	-39	-27	-34	-50
Common Stock	1,559	0.00	1,568	1,570	1,600	1,602	1,605
Retained Earnings	-1,545	-1,584	-1,595	-1,610	-1,627	-1,636	-1,656
Accumulated Other Comprehensive Income / (Loss)	0.01	0.00	0.01	0.01	0.01	0.01	0.01

This table displays calculated financial ratios and metrics derived from Akebia Therapeutics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	38.19%	-33.46%	-17.70%
EBITDA Growth	82.05%	89.94%	-122.54%
EBIT Growth	70.38%	40.88%	-10.49%
NOPAT Growth	69.46%	42.74%	-9.11%
Net Income Growth	66.59%	44.89%	-33.67%
EPS Growth	69.41%	46.15%	-17.86%
Operating Cash Flow Growth	71.08%	68.03%	-73.88%
Free Cash Flow Firm Growth	88.12%	18.71%	7.21%
Invested Capital Growth	-188.08%	-102.66%	-60.62%
Revenue Q/Q Growth	25.66%	-23.93%	-5.71%
EBITDA Q/Q Growth	61.14%	73.29%	-232.36%
EBIT Q/Q Growth	45.04%	12.58%	-54.83%
NOPAT Q/Q Growth	42.81%	11.89%	-45.06%
Net Income Q/Q Growth	41.90%	4.63%	-50.91%
EPS Q/Q Growth	41.57%	12.50%	-50.00%
Operating Cash Flow Q/Q Growth	10.00%	69.13%	-5.61%
Free Cash Flow Firm Q/Q Growth	-132.06%	78.22%	45.46%
Invested Capital Q/Q Growth	70.51%	10.41%	-35.38%
Profitability Metrics	-	-	-
Gross Margin	70.74%	61.90%	60.56%
EBITDA Margin	-13.76%	-2.08%	-5.62%
Operating Margin	-27.62%	-23.77%	-31.51%
EBIT Margin	-26.54%	-23.58%	-31.66%
Profit (Net Income) Margin	-32.22%	-26.68%	-43.33%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	121.37%	113.14%	136.88%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-4,361.38%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-4,263.06%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	4,123.55%	0.00%	0.00%
Return on Equity (ROE)	-237.83%	409.60%	174.03%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-17.54%	-15.36%	-21.93%
Return on Assets (ROA)	-21.28%	-17.37%	-30.02%
Return on Common Equity (ROCE)	-237.83%	409.60%	174.03%
Return on Equity Simple (ROE_SIMPLE)	-1,801.64%	169.78%	141.12%
Net Operating Profit after Tax (NOPAT)	-57	-32	-35
NOPAT Margin	-19.33%	-16.64%	-22.06%
Net Nonoperating Expense Percent (NNEP)	-98.33%	-119.80%	-318.22%
Return On Investment Capital (ROIC_SIMPLE)	-	-789.93%	336.74%
Cost of Revenue to Revenue	29.26%	38.10%	39.44%
SG&A Expenses to Revenue	47.39%	51.50%	66.52%
R&D to Revenue	44.44%	32.41%	23.51%
Operating Expenses to Revenue	98.36%	85.67%	92.07%
Earnings before Interest and Taxes (EBIT)	-78	-46	-51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-40	-4.05	-9.01
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	20.30	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.36	1.20	2.59
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.28	1.16	2.51
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	12.63	-1.13	-0.79
Long-Term Debt to Equity	6.52	-0.56	-0.79
Financial Leverage	-0.97	1.29	0.27
Leverage Ratio	11.17	-23.58	-5.80
Compound Leverage Factor	13.56	-26.68	-7.93
Debt to Total Capital	92.67%	846.13%	-368.79%
Short-Term Debt to Total Capital	44.88%	426.93%	0.00%
Long-Term Debt to Total Capital	47.79%	419.20%	-368.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	7.33%	-746.13%	468.79%
Debt to EBITDA	-1.64	-8.57	-4.30
Net Debt to EBITDA	0.61	2.04	1.46
Long-Term Debt to EBITDA	-0.85	-4.25	-4.30
Debt to NOPAT	-1.17	-1.07	-1.10
Net Debt to NOPAT	0.43	0.25	0.37
Long-Term Debt to NOPAT	-0.60	-0.53	-1.10
Altman Z-Score	-5.65	-8.54	-9.58
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.43	1.18	1.41
Quick Ratio	1.01	0.82	1.07
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-13	-12
Operating Cash Flow to CapEx	-64,170.18%	0.00%	-123,209.09%
Free Cash Flow to Firm to Interest Expense	-17.26	0.00	-22.81
Operating Cash Flow to Interest Expense	-80.74	0.00	-78.64
Operating Cash Flow Less CapEx to Interest Expense	-80.87	0.00	-78.71
Efficiency Ratios	-	-	-
Asset Turnover	0.66	0.65	0.69
Accounts Receivable Turnover	6.37	4.89	4.35
Inventory Turnover	2.94	3.98	3.96
Fixed Asset Turnover	48.88	44.02	54.96
Accounts Payable Turnover	3.32	4.54	4.24
Days Sales Outstanding (DSO)	57.32	74.62	83.92
Days Inventory Outstanding (DIO)	124.12	91.70	92.25
Days Payable Outstanding (DPO)	110.07	80.37	86.13
Cash Conversion Cycle (CCC)	71.37	85.95	90.04
Capital & Investment Metrics	-	-	-
Invested Capital	-19	-39	-62
Invested Capital Turnover	225.60	-6.71	-3.17
Increase / (Decrease) in Invested Capital	-41	-20	-24
Enterprise Value (EV)	82	225	401
Market Capitalization	106	234	415
Book Value per Share	$0.03	($0.16)	($0.23)
Tangible Book Value per Share	($0.68)	($0.67)	($0.50)
Total Capital	71	4.10	-10
Total Debt	66	35	39
Total Long-Term Debt	34	17	39
Net Debt	-24	-8.24	-13
Capital Expenditures (CapEx)	0.11	0.00	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.82	-7.15	-19
Debt-free Net Working Capital (DFNWC)	88	36	33
Net Working Capital (NWC)	56	18	33
Net Nonoperating Expense (NNE)	38	20	34
Net Nonoperating Obligations (NNO)	-24	-8.24	-13
Total Depreciation and Amortization (D&A)	37	42	42
Debt-free, Cash-free Net Working Capital to Revenue	-0.96%	-3.67%	-11.83%
Debt-free Net Working Capital to Revenue	29.97%	18.38%	20.55%
Net Working Capital to Revenue	19.03%	9.39%	20.55%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.51)	($0.28)	($0.33)
Adjusted Weighted Average Basic Shares Outstanding	182.78M	187.47M	210.95M
Adjusted Diluted Earnings per Share	($0.51)	($0.28)	($0.33)
Adjusted Weighted Average Diluted Shares Outstanding	182.78M	187.47M	210.95M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	184.25M	209.37M	236.23M
Normalized Net Operating Profit after Tax (NOPAT)	-45	-32	-35
Normalized NOPAT Margin	-15.52%	-16.57%	-22.03%
Pre Tax Income Margin	-32.22%	-26.68%	-43.33%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-85.69	0.00	-98.08
NOPAT to Interest Expense	-62.41	0.00	-68.34
EBIT Less CapEx to Interest Expense	-85.81	0.00	-98.15
NOPAT Less CapEx to Interest Expense	-62.54	0.00	-68.40
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Akebia Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.09%	103.56%	0.00%	-55.39%	-13.69%	-52.13%	-18.49%	-22.58%	-10.98%	-17.26%
EBITDA Growth	8.88%	107.69%	68.29%	-100.28%	91.04%	267.90%	64.82%	2,520.33%	-9.04%	-115.23%
EBIT Growth	7.44%	92.49%	57.51%	-127.97%	74.05%	141.72%	40.87%	32.50%	-2.29%	-884.20%
NOPAT Growth	8.16%	92.55%	57.04%	-118.48%	74.14%	140.29%	41.65%	3.01%	4.07%	-829.37%
Net Income Growth	9.15%	97.27%	60.28%	-137.94%	73.22%	132.08%	33.08%	23.18%	-38.30%	-3,826.14%
EPS Growth	14.71%	92.50%	57.14%	-140.00%	72.41%	133.33%	40.00%	33.33%	-25.00%	-1,100.00%
Operating Cash Flow Growth	160.08%	12.94%	18.88%	111.84%	-121.20%	95.78%	-10.80%	-377.38%	6.59%	-93.50%
Free Cash Flow Firm Growth	-4.80%	379.70%	-475.61%	-7.92%	-154.08%	-43.89%	179.79%	-120.30%	80.40%	-35.74%
Invested Capital Growth	-339.04%	-188.08%	272.62%	-425.07%	33.29%	-102.66%	-171.00%	7.05%	-6.29%	-60.62%
Revenue Q/Q Growth	-61.45%	141.01%	-65.93%	40.92%	-25.42%	33.65%	-41.98%	33.86%	-14.25%	24.23%
EBITDA Q/Q Growth	-194.21%	110.38%	-473.82%	99.23%	-2,885.37%	526.31%	-143.82%	153.21%	-234.50%	40.46%
EBIT Q/Q Growth	-247.92%	90.34%	-420.03%	62.35%	-37.24%	115.53%	-1,190.31%	57.03%	-107.96%	-19.05%
NOPAT Q/Q Growth	-203.55%	90.34%	-425.82%	64.86%	-44.91%	115.05%	-861.49%	41.58%	-43.32%	-14.40%
Net Income Q/Q Growth	-283.69%	96.47%	-1,308.60%	58.43%	-29.69%	104.22%	-3,038.73%	52.28%	-133.50%	-13.80%
EPS Q/Q Growth	-293.33%	89.66%	-400.00%	60.00%	-33.33%	112.50%	-1,000.00%	55.56%	-150.00%	0.00%
Operating Cash Flow Q/Q Growth	210.26%	-261.75%	67.93%	120.69%	-297.49%	67.80%	-741.94%	48.20%	33.49%	33.29%
Free Cash Flow Firm Q/Q Growth	21.03%	-34.04%	-379.56%	141.26%	-171.09%	168.43%	297.58%	-110.49%	31.36%	324.41%
Invested Capital Q/Q Growth	-657.27%	70.51%	387.28%	-168.85%	-14.37%	10.41%	-0.64%	9.86%	-30.79%	-35.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	21.42%	95.25%	49.53%	69.34%	57.17%	66.78%	64.41%	60.94%	62.16%	56.20%
EBITDA Margin	-84.13%	3.62%	-39.76%	-0.22%	-8.73%	27.86%	-17.16%	6.82%	-10.70%	-5.13%
Operating Margin	-103.47%	-4.15%	-63.98%	-15.96%	-31.00%	2.44%	-45.81%	-19.99%	-33.41%	-30.77%
EBIT Margin	-103.47%	-4.15%	-63.28%	-16.90%	-31.11%	3.61%	-45.91%	-14.74%	-35.74%	-34.25%
Profit (Net Income) Margin	-111.05%	-1.63%	-67.18%	-19.82%	-34.46%	1.09%	-55.16%	-19.66%	-53.54%	-49.04%
Tax Burden Percent	97.89%	578.18%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	109.64%	6.78%	106.17%	117.23%	110.78%	30.13%	120.14%	133.41%	149.79%	143.18%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-654.77%	-1,286.39%	0.00%	0.00%	0.00%	-752.14%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-658.69%	-1,286.96%	0.00%	0.00%	0.00%	-753.07%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	637.13%	1,296.54%	0.00%	0.00%	0.00%	760.53%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-214.80%	-17.64%	10.15%	12.35%	425.87%	409.60%	8.39%	133.56%	102.41%	174.03%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-217.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-46.40%	-2.74%	-51.15%	-11.33%	-23.72%	2.35%	-33.95%	-10.85%	-27.47%	-23.73%
Return on Assets (ROA)	-49.79%	-1.07%	-54.30%	-13.28%	-26.28%	0.71%	-40.78%	-14.48%	-41.14%	-33.98%
Return on Common Equity (ROCE)	-214.80%	-17.64%	10.15%	12.35%	425.87%	409.60%	8.39%	133.56%	102.41%	174.03%
Return on Equity Simple (ROE_SIMPLE)	-1,170.72%	0.00%	279.38%	350.85%	138.11%	0.00%	157.88%	119.82%	91.25%	0.00%
Net Operating Profit after Tax (NOPAT)	-35	-3.41	-18	-6.30	-9.13	1.37	-10	-6.11	-8.75	-10
NOPAT Margin	-72.43%	-2.90%	-44.79%	-11.17%	-21.70%	2.44%	-32.06%	-13.99%	-23.39%	-21.54%
Net Nonoperating Expense Percent (NNEP)	-19.93%	3.91%	0.57%	0.65%	-12.97%	-4.66%	0.93%	-39.42%	5,374.05%	-119.42%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	33.50%	-	-	-	95.45%
Cost of Revenue to Revenue	78.58%	4.75%	50.47%	30.66%	42.83%	33.22%	35.59%	39.06%	37.84%	43.80%
SG&A Expenses to Revenue	65.46%	25.47%	62.62%	47.96%	54.01%	45.26%	78.01%	61.67%	70.85%	59.52%
R&D to Revenue	57.54%	64.67%	49.21%	35.83%	31.70%	17.56%	29.84%	17.52%	22.68%	25.35%
Operating Expenses to Revenue	124.89%	92.50%	113.52%	85.30%	88.17%	64.34%	110.22%	80.93%	95.58%	86.97%
Earnings before Interest and Taxes (EBIT)	-50	-4.87	-25	-9.53	-13	2.03	-15	-6.43	-13	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-41	4.26	-16	-0.12	-3.67	16	-5.60	2.98	-4.00	-2.38
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.20	20.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.25	0.36	0.31	0.65	0.84	1.20	2.05	1.23	1.63	2.59
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	1.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.28	0.31	0.61	0.82	1.16	1.98	1.22	1.66	2.51
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	92.01	29.75	41.43	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	5.37	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	4.76	12.63	0.00	-1.58	-1.08	-1.13	-1.11	-1.13	-0.76	-0.79
Long-Term Debt to Equity	0.00	6.52	0.00	-0.69	-0.88	-0.56	-1.11	-1.13	-0.76	-0.79
Financial Leverage	-1.25	-0.97	-1.01	-0.98	3.24	1.29	-1.01	0.21	0.00	0.27
Leverage Ratio	6.88	11.17	-0.26	-0.51	-26.24	-23.58	-0.31	-7.83	-4.92	-5.80
Compound Leverage Factor	7.54	0.76	-0.28	-0.60	-29.07	-7.10	-0.38	-10.44	-7.37	-8.30
Debt to Total Capital	82.64%	92.67%	0.00%	270.97%	1,335.41%	846.13%	1,044.16%	889.20%	-318.38%	-368.79%
Short-Term Debt to Total Capital	82.64%	44.88%	0.00%	153.07%	250.71%	426.93%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	47.79%	0.00%	117.90%	1,084.71%	419.20%	1,044.16%	889.20%	-318.38%	-368.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	17.36%	7.33%	100.00%	-170.97%	-1,235.41%	-746.13%	-944.16%	-789.20%	418.38%	468.79%
Debt to EBITDA	-0.64	-1.64	0.00	-0.81	-2.81	-8.57	7.47	5.33	5.64	-4.30
Net Debt to EBITDA	0.76	0.61	0.00	0.21	0.26	2.04	-2.93	-0.21	0.64	1.46
Long-Term Debt to EBITDA	0.00	-0.85	0.00	-0.35	-2.28	-4.25	7.47	5.33	5.64	-4.30
Debt to NOPAT	-0.67	-1.17	0.00	-0.68	-1.16	-1.07	-1.21	-1.54	-1.57	-1.10
Net Debt to NOPAT	0.80	0.43	0.00	0.18	0.11	0.25	0.47	0.06	-0.18	0.37
Long-Term Debt to NOPAT	0.00	-0.60	0.00	-0.29	-0.94	-0.53	-1.21	-1.54	-1.57	-1.10
Altman Z-Score	-4.59	-4.98	-6.66	-7.40	-8.06	-7.88	-8.33	-9.17	-9.74	-9.06
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.26	1.43	1.38	1.28	1.38	1.18	1.70	1.04	1.52	1.41
Quick Ratio	0.89	1.01	0.21	0.79	0.87	0.82	1.03	0.65	1.01	1.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	57	38	-105	43	-31	21	84	-8.78	-6.03	14
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-334,750.00%	-223,300.00%
Free Cash Flow to Firm to Interest Expense	62.75	0.00	0.00	0.00	0.00	0.00	161.81	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	37.31	0.00	0.00	0.00	0.00	0.00	-37.59	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	37.31	0.00	0.00	0.00	0.00	0.00	-37.59	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.66	0.81	0.67	0.76	0.65	0.74	0.74	0.77	0.69
Accounts Receivable Turnover	6.40	6.37	7.91	5.17	11.20	4.89	8.26	7.07	6.20	4.35
Inventory Turnover	3.46	2.94	2.69	2.66	2.09	3.98	2.85	2.92	3.16	3.96
Fixed Asset Turnover	36.32	48.88	0.00	0.00	53.05	44.02	0.00	47.72	51.82	54.96
Accounts Payable Turnover	5.26	3.32	0.00	0.00	4.25	4.54	0.00	5.97	5.46	4.24
Days Sales Outstanding (DSO)	57.07	57.32	46.16	70.62	32.59	74.62	44.21	51.60	58.83	83.92
Days Inventory Outstanding (DIO)	105.44	124.12	135.81	137.16	174.78	91.70	127.88	125.09	115.58	92.25
Days Payable Outstanding (DPO)	69.39	110.07	0.00	0.00	85.91	80.37	0.00	61.13	66.89	86.13
Cash Conversion Cycle (CCC)	93.12	71.37	181.97	207.78	121.46	85.95	172.09	115.56	107.52	90.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-65	-19	55	-38	-43	-39	-39	-35	-46	-62
Invested Capital Turnover	-12.32	225.60	28.72	-20.01	-4.72	-6.71	23.46	-4.77	-3.80	-3.17
Increase / (Decrease) in Invested Capital	-92	-41	87	-50	22	-20	-94	2.67	-2.73	-24
Enterprise Value (EV)	-21	82	103	159	211	225	371	212	282	401
Market Capitalization	58	106	103	170	215	234	383	214	278	415
Book Value per Share	$0.08	$0.03	($8.60)	($0.14)	($0.21)	($0.16)	($0.13)	($0.16)	($0.24)	($0.23)
Tangible Book Value per Share	($0.67)	($0.68)	($8.92)	($0.75)	($0.76)	($0.67)	($0.54)	($0.53)	($0.56)	($0.50)
Total Capital	80	71	-1,584	16	3.19	4.10	2.89	4.28	-12	-10
Total Debt	66	66	0.00	42	43	35	30	38	38	39
Total Long-Term Debt	0.00	34	0.00	18	35	17	30	38	38	39
Net Debt	-79	-24	0.00	-11	-3.92	-8.24	-12	-1.47	4.34	-13
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-29	-2.82	33	-3.31	-8.63	-7.15	4.50	-35	0.39	-19
Debt-free Net Working Capital (DFNWC)	115	88	33	50	38	36	46	4.80	34	33
Net Working Capital (NWC)	50	56	33	26	30	18	46	4.80	34	33
Net Nonoperating Expense (NNE)	19	-1.50	8.96	4.87	5.36	0.76	7.53	2.47	11	13
Net Nonoperating Obligations (NNO)	-79	-24	1,639	-11	-3.92	-8.24	-12	-1.47	4.34	-13
Total Depreciation and Amortization (D&A)	9.42	9.12	9.41	9.41	9.41	14	9.38	9.41	9.37	14
Debt-free, Cash-free Net Working Capital to Revenue	-12.57%	-0.96%	9.97%	-1.26%	-3.37%	-3.67%	2.40%	-19.89%	0.23%	-11.83%
Debt-free Net Working Capital to Revenue	49.62%	29.97%	9.97%	19.15%	14.81%	18.38%	24.81%	2.75%	20.26%	20.55%
Net Working Capital to Revenue	21.29%	19.03%	9.97%	10.01%	11.69%	9.39%	24.81%	2.75%	20.26%	20.55%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.28)	($0.04)	$0.00	$0.00	($0.08)	$0.01	($0.09)	($0.04)	($0.10)	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	183.88M	182.78M	0.00	0.00	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M
Adjusted Diluted Earnings per Share	($0.28)	($0.03)	$0.00	$0.00	($0.08)	$0.01	($0.09)	($0.04)	($0.10)	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	183.88M	182.78M	0.00	0.00	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	183.96M	184.25M	0.00	0.00	188.39M	209.37M	209.60M	210.29M	218.18M	236.23M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-2.55	-18	-6.36	-9.01	0.96	-10	-6.11	-8.75	-10
Normalized NOPAT Margin	-72.17%	-2.17%	-44.60%	-11.29%	-21.42%	1.71%	-31.94%	-13.99%	-23.39%	-21.54%
Pre Tax Income Margin	-113.44%	-0.28%	-67.18%	-19.82%	-34.46%	1.09%	-55.16%	-19.66%	-53.54%	-49.04%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-55.63	0.00	0.00	0.00	0.00	0.00	-28.96	0.00	0.00	0.00
NOPAT to Interest Expense	-38.94	0.00	0.00	0.00	0.00	0.00	-20.22	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-55.63	0.00	0.00	0.00	0.00	0.00	-28.96	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-38.94	0.00	0.00	0.00	0.00	0.00	-20.22	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Akebia Therapeutics' Financials

When does Akebia Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Akebia Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Akebia Therapeutics' net income changed over the last 2 years?

Akebia Therapeutics' net income appears to be on a downward trend, with a most recent value of -$69.41 million in 2024, falling from -$94.23 million in 2022. The previous period was -$51.93 million in 2023.

What is Akebia Therapeutics's operating income?

Akebia Therapeutics's total operating income in 2024 was -$50.47 million, based on the following breakdown:

Total Gross Profit: $97.00 million
Total Operating Expenses: $147.48 million

How has Akebia Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Akebia Therapeutics' total revenue changed from $292.48 million in 2022 to $160.18 million in 2024, a change of -45.2%.

How much debt does Akebia Therapeutics have?

Akebia Therapeutics' total liabilities were at $269.86 million at the end of 2024, a 0.9% decrease from 2023, and a 23.1% decrease since 2022.

How much cash does Akebia Therapeutics have?

In the past 2 years, Akebia Therapeutics' cash and equivalents has ranged from $42.93 million in 2023 to $90.47 million in 2022, and is currently $51.87 million as of their latest financial filing in 2024.

How has Akebia Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Akebia Therapeutics' book value per share changed from 0.03 in 2022 to -0.23 in 2024, a change of -893.7%.

Related Companies

This page (NASDAQ:AKBA) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Financials

Frequently Asked Questions About Akebia Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Financials

Annual Income Statements for Akebia Therapeutics

Quarterly Income Statements for Akebia Therapeutics

Annual Cash Flow Statements for Akebia Therapeutics

Quarterly Cash Flow Statements for Akebia Therapeutics

Annual Balance Sheets for Akebia Therapeutics

Quarterly Balance Sheets for Akebia Therapeutics

Annual Metrics and Ratios for Akebia Therapeutics

Quarterly Metrics and Ratios for Akebia Therapeutics

Frequently Asked Questions About Akebia Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools